Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $49,399.84 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 6,301 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $7.84, for a total value of $49,399.84. Following the sale, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. This trade represents a 2.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Donald Notman also recently made the following trade(s):

• On Tuesday, February 4th, Donald Notman sold 11,119 shares of Ocular Therapeutix stock. The stock was sold at an average price of $7.81, for a total value of $86,839.39.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL traded up $0.27 during midday trading on Tuesday, reaching $7.82. The stock had a trading volume of 904,622 shares, compared to its average volume of 904,992. The stock has a market capitalization of $1.23 billion, a P/E ratio of -5.92 and a beta of 1.22. Ocular Therapeutix, Inc. has a 1-year low of $4.06 and a 1-year high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The firm’s fifty day simple moving average is $8.61 and its 200-day simple moving average is $9.02.

Wall Street Analyst Weigh In

Several research analysts have commented on OCUL shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. Scotiabank assumed coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.71.

Hedge Funds Weigh In On Ocular Therapeutix

Institutional investors have recently made changes to their positions in the business. Hussman Strategic Advisors Inc. bought a new position in Ocular Therapeutix in the 4th quarter worth approximately $897,000. New York State Common Retirement Fund raised its stake in shares of Ocular Therapeutix by 18.4% in the fourth quarter. New York State Common Retirement Fund now owns 98,097 shares of the biopharmaceutical company’s stock valued at $838,000 after purchasing an additional 15,239 shares in the last quarter. Truist Financial Corp bought a new position in Ocular Therapeutix in the fourth quarter worth $427,000. Palumbo Wealth Management LLC acquired a new stake in Ocular Therapeutix during the fourth quarter worth $100,000. Finally, Rhumbline Advisers increased its holdings in Ocular Therapeutix by 2.7% in the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 5,682 shares during the period. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.